A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.
Lung Cancer|Bronchial Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Sarcoma|Colorectal Cancer|Gastric Cancer|Liver Cancer|Breast Cancer|Pancreatic Cancer|Head and Neck Cancer|Ovarian Cancer
DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)
Subject incidence of adverse events, To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0), Up to 6 months|Subject incidence of laboratory abnormalities, Detection of liver and renal function, electrocardiogram, routine blood examination etc., Up to 1 month|Systemic Immune Response, Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa，IFNγ, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS), Up to 6 months
Disease Assessment for Disease Control Rate, Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST, Every 10 weeks for 12 months|Disease Assessment for Duration of Response, Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST, Every 10 weeks for 12 months|Quality of Life Assessment, Evaluate with EORTC QLQ-C30, Every 6 weeks for 12 months
24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.